I'll pull the relevant safety profile, precedent criteria, and lab thresholds to ground this in precedent.
{
"drug_class": "DLL3 T-cell engager",
"class_effect_aes": [
"Cytokine release syndrome (CRS) \u2014 common, mostly cycle-1, can be high-grade",
"Immune effector cell-associated neurotoxicity syndrome (ICANS) / neurotoxicity",
"Cytopenias (neutropenia, anemia, thrombocytopenia)",
"Hypogammaglobulinemia / infection risk from on-target B/neuroendocrine effects",
"Tumor flare / pyrexia"
],
"monitoring": [
"Inpatient monitoring for CRS during step-up/priming doses (cycle 1)",
"Frequent vitals, ferritin/CRP trend during CRS window",
"Baseline + on-treatment neuro exam (ICE score) for ICANS",
"Baseline ECG/echo if cardiac reserve is a concern during CRS",
"CBC with differential before each dose"
],
"contraindicated_comorbidities": [
"Active CNS metastases / leptomeningeal disease (raises ICANS danger)",
"Active autoimmune CNS disease or seizure disorder",
"Inadequate cardiac reserve (CRS hemodynamic stress) \u2014 recent MI, NYHA III/IV CHF",
"Active uncontrolled infection (CRS masks/worsens sepsis)",
"Significant baseline hypoxia / poor pulmonary reserve"
],
"ddi_flags": [
"Live vaccines contraindicated (immune activation)",
"Chronic systemic immunosuppression / high-dose steroids blunt efficacy and confound CRS grading",
"Tocilizumab/steroids must be available on-site as CRS rescue"
],
"notes": "First-in-human TCEs need a step-up/priming dose schedule and mandated CRS/ICANS rescue medication on hand; cycle-1 inpatient observation is standard."
}{
"indication": "ES-SCLC",
"precedent_trials": [
"Tarlatamab DeLLphi-301/304 (DLL3 TCE)",
"IMpower133 (1L chemo-IO)"
],
"inclusion": [
"Histologically/cytologically confirmed extensive-stage SCLC",
"Relapsed/refractory after >=1 prior platinum-based regimen (line per protocol)",
"Measurable disease per RECIST v1.1",
"ECOG performance status 0-1",
"Adequate hematologic, hepatic, renal organ function (see lab thresholds)",
"Life expectancy >=12 weeks"
],
"exclusion": [
"Untreated/active/symptomatic CNS metastases (treated, stable may be allowed)",
"Leptomeningeal disease / carcinomatous meningitis",
"Active autoimmune disease or condition needing systemic immunosuppression (for IO/TCE)",
"Insufficient washout from prior anticancer therapy (e.g. ~3-4 wks or 5 half-lives)",
"Uncontrolled intercurrent illness / active infection",
"Second malignancy requiring active treatment"
],
"notes": "DLL3 TCE precedents often allow treated/stable brain mets but exclude active CNS disease specifically because of ICANS/neurotoxicity risk."
}{
"hematologic": [
{
"parameter": "Absolute neutrophil count (ANC)",
"typical_threshold": ">= 1.5 x 10^9/L",
"rationale": "Adequate marrow reserve before a myelosuppressive agent; lower (>=1.0) sometimes allowed if marrow involvement."
},
{
"parameter": "Platelets",
"typical_threshold": ">= 100 x 10^9/L (>=75 if marrow involvement)",
"rationale": "Bleeding risk and tolerance of thrombocytopenia."
},
{
"parameter": "Hemoglobin",
"typical_threshold": ">= 9.0 g/dL (transfusion-independent)",
"rationale": "Baseline reserve; many protocols require independence from recent transfusion."
}
],
"hepatic": [
{
"parameter": "Total bilirubin",
"typical_threshold": "<= 1.5 x ULN (<=3 x ULN if Gilbert's/liver mets)",
"rationale": "Hepatic clearance reserve; relaxed for documented Gilbert's or hepatic metastases."
},
{
"parameter": "AST / ALT",
"typical_threshold": "<= 3 x ULN (<=5 x ULN if liver metastases)",
"rationale": "Baseline hepatocellular integrity; key for hepatotoxic agents (PI3Ki, JAKi)."
},
{
"parameter": "Albumin",
"typical_threshold": ">= 2.8-3.0 g/dL (some protocols)",
"rationale": "Synthetic liver function / nutritional status, esp. GI cancers."
}
],
"renal": [
{
"parameter": "Creatinine clearance (Cockcroft-Gault)",
"typical_threshold": ">= 50-60 mL/min",
"rationale": "Renal elimination reserve; threshold depends on renal clearance of the drug."
},
{
"parameter": "Serum creatinine",
"typical_threshold": "<= 1.5 x ULN",
"rationale": "Simpler surrogate when CrCl not used."
}
],
"cardiac": [
{
"parameter": "Left-ventricular ejection fraction (LVEF)",
"typical_threshold": ">= 50% (institutional LLN)",
"rationale": "Required for cardiotoxic agents (anti-HER2, anthracycline exposure)."
},
{
"parameter": "QTc (Fridericia)",
"typical_threshold": "<= 470 ms (women) / <= 450 ms (men)",
"rationale": "Exclude baseline prolongation for QT-liable agents; pair with congenital long-QT exclusion."
}
],
"coagulation_metabolic": [
{
"parameter": "INR / aPTT (if on anticoagulation off-study)",
"typical_threshold": "within therapeutic range / <= 1.5 x ULN",
"rationale": "Bleeding risk, esp. for agents with hemorrhage signal (BTKi)."
},
{
"parameter": "Fasting glucose / HbA1c",
"typical_threshold": "HbA1c <= 6.5-8.0% per protocol",
"rationale": "Baseline glycemic control for hyperglycemia-liable agents (PI3K-alpha)."
}
],
"notes": "Teaching-snapshot typical oncology cutoffs. Exact thresholds and relaxations (marrow involvement, liver mets, Gilbert's) are drug- and protocol-specific and must be set against the investigator's brochure and standard of care."
}Authored against DLL3 TCE precedent (tarlatamab DeLLphi-301/304) and TCE class-effect safety (CRS, ICANS, on-target neuroendocrine effects). Design intent: protect against the cycle-1 CRS/ICANS window while keeping a heavily pretreated ES-SCLC population enrollable.
Disease
1. Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
2. Relapsed or refractory disease after ≥1 prior platinum-based regimen. (FIH dose-escalation: do not over-restrict prior lines — allow ≥1 to maximize the eligible pool; a sensitive- vs. platinum-refractory stratification factor is preferable to an exclusion.)
3. At least one measurable lesion per RECIST v1.1.
4. Available archival or fresh tumor tissue (DLL3 expression may be collected as a biomarker but not required for eligibility in a FIH study, to preserve enrollability and characterize the expression–response relationship).
Performance / reserve
5. ECOG performance status 0–1.
6. Life expectancy ≥12 weeks.
Organ function (within 7–14 days of first dose)
7. ANC ≥1.5 ×10⁹/L (≥1.0 acceptable if documented marrow involvement).
8. Platelets ≥100 ×10⁹/L (≥75 if marrow involvement).
9. Hemoglobin ≥9.0 g/dL, transfusion-independent for ≥2 weeks.
10. Total bilirubin ≤1.5× ULN (≤3× ULN if Gilbert's or hepatic metastases).
11. AST/ALT ≤3× ULN (≤5× ULN if hepatic metastases).
12. Creatinine clearance ≥50 mL/min (Cockcroft-Gault) or serum creatinine ≤1.5× ULN.
13. Adequate coagulation if on anticoagulation: INR/aPTT within therapeutic range.
Safety-context (TCE-specific)
14. Adequate cardiac reserve to tolerate CRS hemodynamic stress: LVEF ≥50%; no QTc prolongation (>470 ms women / >450 ms men).
15. Adequate pulmonary reserve: baseline O₂ saturation ≥92% on room air, no supplemental-oxygen dependence — CRS-associated hypoxia is a key cycle-1 hazard.
16. Baseline normal/near-normal neurologic exam with documented baseline ICE score, to enable ICANS detection.
17. Willing/able to be hospitalized for inpatient monitoring during step-up/priming doses (cycle 1).
18. Recovered to ≤Grade 1 from prior-therapy toxicities (excluding alopecia, stable neuropathy).
CNS / neurotoxicity risk (heightened priority for a TCE — ICANS)
1. Active, untreated, or symptomatic CNS metastases. (Treated, stable, asymptomatic brain mets — radiographically stable ≥4 weeks, off steroids ≥7 days — may be ALLOWED; precedent permits this and excluding all brain mets would gut SCLC enrollability.)
2. Leptomeningeal disease / carcinomatous meningitis (absolute exclusion — disproportionate ICANS danger).
3. History of seizure disorder, or active CNS autoimmune/inflammatory disease (confounds and amplifies ICANS).
Immune / infection (CRS confounders)
4. Active autoimmune disease requiring systemic immunosuppression within the prior 2 years (well-controlled endocrinopathies on replacement, e.g., thyroid, are permitted).
5. Chronic systemic corticosteroids >10 mg/day prednisone-equivalent or other immunosuppression at screening (blunts efficacy, confounds CRS grading) — taper required pre-dose.
6. Active, uncontrolled infection (CRS masks/worsens sepsis); known active HIV (unless controlled per protocol), active HBV/HCV.
Cardiopulmonary (CRS tolerance)
7. Myocardial infarction or unstable angina within 6 months; NYHA Class III/IV heart failure; clinically significant uncontrolled arrhythmia.
8. Interstitial lung disease/pneumonitis requiring steroids, or clinically significant baseline hypoxia.
General oncology
9. Insufficient washout from prior anticancer therapy (≥3–4 weeks or 5 half-lives, whichever shorter; ≥2 weeks for palliative RT).
10. Second malignancy requiring active treatment (excluding adequately treated in-situ/non-melanoma skin cancers).
11. Uncontrolled intercurrent illness.
12. Live vaccine within 4 weeks of first dose (contraindicated with immune activation).
13. Pregnancy/lactation; refusal of effective contraception.
| Tension | Decision | Why |
|---|---|---|
| Brain mets | Exclude active; allow treated/stable | ES-SCLC has high CNS-met prevalence; full exclusion would cripple accrual. ICANS risk managed via "active/symptomatic" and LMD carve-outs. |
| Prior lines | ≥1 only, stratify rather than cap | FIH should access the broadest R/R pool; refractory status captured as covariate. |
| DLL3 expression | Not required for eligibility | Preserves enrollability and lets the study define the expression–response relationship in dose-escalation. |
| Cardiopulmonary bars | Added explicit O₂ sat + LVEF/QTc + recent-MI/CHF exclusions | These are TCE-specific additions beyond generic SCLC criteria — CRS imposes hemodynamic/hypoxic stress not present with chemo. |
| Steroids | Threshold (≤10 mg) rather than absolute ban | Allows physiologic replacement; protects efficacy and clean CRS grading. |
Teaching/precedent-grounded draft. Exact thresholds, washouts, and brain-met stability windows must be finalized against the Investigator's Brochure, the specific step-up schedule, and regulatory input.
Want me to draft the matching CRS/ICANS management and dose-modification tables, or the stratification/dose-escalation (e.g., BOIN/3+3) design to pair with these criteria?
Authored against DLL3 TCE precedent (tarlatamab DeLLphi-301/304) and TCE class-effect safety (CRS, ICANS, on-target neuroendocrine effects). Design intent: protect against the cycle-1 CRS/ICANS window while keeping a heavily pretreated ES-SCLC population enrollable.
Disease
1. Histologically or cytologically confirmed extensive-stage small cell lung cancer (ES-SCLC).
2. Relapsed or refractory disease after ≥1 prior platinum-based regimen. (FIH dose-escalation: do not over-restrict prior lines — allow ≥1 to maximize the eligible pool; a sensitive- vs. platinum-refractory stratification factor is preferable to an exclusion.)
3. At least one measurable lesion per RECIST v1.1.
4. Available archival or fresh tumor tissue (DLL3 expression may be collected as a biomarker but not required for eligibility in a FIH study, to preserve enrollability and characterize the expression–response relationship).
Performance / reserve
5. ECOG performance status 0–1.
6. Life expectancy ≥12 weeks.
Organ function (within 7–14 days of first dose)
7. ANC ≥1.5 ×10⁹/L (≥1.0 acceptable if documented marrow involvement).
8. Platelets ≥100 ×10⁹/L (≥75 if marrow involvement).
9. Hemoglobin ≥9.0 g/dL, transfusion-independent for ≥2 weeks.
10. Total bilirubin ≤1.5× ULN (≤3× ULN if Gilbert's or hepatic metastases).
11. AST/ALT ≤3× ULN (≤5× ULN if hepatic metastases).
12. Creatinine clearance ≥50 mL/min (Cockcroft-Gault) or serum creatinine ≤1.5× ULN.
13. Adequate coagulation if on anticoagulation: INR/aPTT within therapeutic range.
Safety-context (TCE-specific)
14. Adequate cardiac reserve to tolerate CRS hemodynamic stress: LVEF ≥50%; no QTc prolongation (>470 ms women / >450 ms men).
15. Adequate pulmonary reserve: baseline O₂ saturation ≥92% on room air, no supplemental-oxygen dependence — CRS-associated hypoxia is a key cycle-1 hazard.
16. Baseline normal/near-normal neurologic exam with documented baseline ICE score, to enable ICANS detection.
17. Willing/able to be hospitalized for inpatient monitoring during step-up/priming doses (cycle 1).
18. Recovered to ≤Grade 1 from prior-therapy toxicities (excluding alopecia, stable neuropathy).
CNS / neurotoxicity risk (heightened priority for a TCE — ICANS)
1. Active, untreated, or symptomatic CNS metastases. (Treated, stable, asymptomatic brain mets — radiographically stable ≥4 weeks, off steroids ≥7 days — may be ALLOWED; precedent permits this and excluding all brain mets would gut SCLC enrollability.)
2. Leptomeningeal disease / carcinomatous meningitis (absolute exclusion — disproportionate ICANS danger).
3. History of seizure disorder, or active CNS autoimmune/inflammatory disease (confounds and amplifies ICANS).
Immune / infection (CRS confounders)
4. Active autoimmune disease requiring systemic immunosuppression within the prior 2 years (well-controlled endocrinopathies on replacement, e.g., thyroid, are permitted).
5. Chronic systemic corticosteroids >10 mg/day prednisone-equivalent or other immunosuppression at screening (blunts efficacy, confounds CRS grading) — taper required pre-dose.
6. Active, uncontrolled infection (CRS masks/worsens sepsis); known active HIV (unless controlled per protocol), active HBV/HCV.
Cardiopulmonary (CRS tolerance)
7. Myocardial infarction or unstable angina within 6 months; NYHA Class III/IV heart failure; clinically significant uncontrolled arrhythmia.
8. Interstitial lung disease/pneumonitis requiring steroids, or clinically significant baseline hypoxia.
General oncology
9. Insufficient washout from prior anticancer therapy (≥3–4 weeks or 5 half-lives, whichever shorter; ≥2 weeks for palliative RT).
10. Second malignancy requiring active treatment (excluding adequately treated in-situ/non-melanoma skin cancers).
11. Uncontrolled intercurrent illness.
12. Live vaccine within 4 weeks of first dose (contraindicated with immune activation).
13. Pregnancy/lactation; refusal of effective contraception.
| Tension | Decision | Why |
|---|---|---|
| Brain mets | Exclude active; allow treated/stable | ES-SCLC has high CNS-met prevalence; full exclusion would cripple accrual. ICANS risk managed via "active/symptomatic" and LMD carve-outs. |
| Prior lines | ≥1 only, stratify rather than cap | FIH should access the broadest R/R pool; refractory status captured as covariate. |
| DLL3 expression | Not required for eligibility | Preserves enrollability and lets the study define the expression–response relationship in dose-escalation. |
| Cardiopulmonary bars | Added explicit O₂ sat + LVEF/QTc + recent-MI/CHF exclusions | These are TCE-specific additions beyond generic SCLC criteria — CRS imposes hemodynamic/hypoxic stress not present with chemo. |
| Steroids | Threshold (≤10 mg) rather than absolute ban | Allows physiologic replacement; protects efficacy and clean CRS grading. |
Teaching/precedent-grounded draft. Exact thresholds, washouts, and brain-met stability windows must be finalized against the Investigator's Brochure, the specific step-up schedule, and regulatory input.
Want me to draft the matching CRS/ICANS management and dose-modification tables, or the stratification/dose-escalation (e.g., BOIN/3+3) design to pair with these criteria?
Expected-coverage checklist for drug class 'DLL3 T-cell engager' — a grading aid, NOT ground truth. A strong I/E list visibly protects against each liability (exclusion / lab cutoff / monitoring) while keeping the target population enrollable.
| Class-effect liability to address | Why it constrains eligibility |
|---|---|
| Cytokine release syndrome (CRS) — common, mostly cycle-1, can be high-grade | Drives cycle-1 inpatient monitoring + exclude poor cardiac/pulmonary reserve and active infection. |
| Immune effector cell-associated neurotoxicity syndrome (ICANS) / neurotoxicity | Exclude active CNS mets / leptomeningeal / seizure disorder; baseline neuro exam. |
| Cytopenias (neutropenia, anemia, thrombocytopenia) | Set ANC/platelet/hemoglobin thresholds; CBC monitoring. |
| Hypogammaglobulinemia / infection risk from on-target B/neuroendocrine effects | Baseline TB/HBV/HCV screening; exclude active/latent untreated infection. |
| Tumor flare / pyrexia | Should be reflected in an exclusion, lab threshold, or monitoring requirement. |